Official Gene Symbol | |
---|---|
Official Full Name | |
Other Aliases | |
Other Designations | |
Chromosome Location | |
Gene Type | |
NCBI Gene ID |
We are sorry to inform you that our system has failed to automatically generate the strategy you have requested due to some genes that do not meet all the criteria required by the strategy. For further support, please contact us at 408-969-0306 or email to [email protected], and our expert will tailor a strategy for you.
Full Name | |
---|---|
Aliases | |
Chromosome Location | |
Gene Type | |
NCBI Gene ID |
We are sorry to inform you that this gene has not yet been included in our point mutation mouse protocol design system, which may be due to the tool’s dynamic updates. If you need the associated point mutation mouseratmodel strategy, please contact us at 408-969-0306 or email to [email protected], and our expert will tailor a strategy for you.
Full Name | |
---|---|
Aliases | |
Chromosome Location | |
Gene Type | |
NCBI Gene ID |
We are sorry to inform you that our system has failed to automatically generate the strategy you have requested due to the design complexity. For further support, please kindly provide your contact information so we can quickly respond to your needs. We also welcome you to send in your request to [email protected] or contact us at 408-969-0306.
Official Gene Symbol | |
---|---|
Official Full Name | |
Other Aliases | |
Other Designations | |
Chromosome Location | |
Gene Type | |
NCBI Gene ID |
We are sorry to inform you that our system has failed to automatically generate the strategy you have requested due to the design complexity. For further support, please kindly provide your contact information so we can quickly respond to your needs. We also welcome you to send in your request to [email protected] or contact us at 408-969-0306.
Accession | Cell Line Name | Strategy |
---|---|---|
View KO Proposal |
We are sorry to inform you that our system has failed to automatically generate the strategy you have requested due to the design complexity. For further support, please kindly provide your contact information so we can quickly respond to your needs. We also welcome you to send in your request to [email protected] or contact us at 408-969-0306.
Typically, experts may need one to two hours to manually formulate a gene targeting strategy that accurately determines the result of gene targeting. During the formulation process, dozens of factors need to be considered and further weighed by their relative importance. Even for the experts who have rich experience, mistakes are inevitable. Additionally, the standards of the best strategy are not objective. Developed by Cyagen, the AlphaKnockout Gene Targeting Expert System provides unbiased strategy design for genetically engineered mouse models by leveraging artificial intelligence (AI) and a robust cloud server that can compute complex biological information algorithms - available as a complimentary resource to researchers and scientists worldwide.
After researchers obtain clinical samples, next-generation sequencing (NGS) and genome-wide association studies (GWAS) may be used to identify many single nucleotide polymorphisms (SNPs) and candidate loci. However, to verify the correlation between these loci and clinical results, in vivo experiments are required. Point mutation mice can work as an excellent research tool for more detailed studies at this stage.
Search by gene target on Cyagen’s Point Mutation Strategy Design System for one-click access to point mutation mouse models, relevant mutation site research literature, clinical disease characteristics, and custom gene targeting strategy reports. Together, these tools can directly serve as valuable information and materials for clinical research, drug development, and molecular diagnostics in precision medicine. Beyond serving as a practical tool, it is also a system designed to inspire researchers seeking to understand the point mutant mouse model construction process via source-based data analysis.
MicroRNAs (miRNAs) play an essential role in cell differentiation, biological development, and the development of disease. Alongside the in-depth studies of the relationship between microRNAs and diseases with the use of high-throughput technologies such as microRNA microarray chips , the collective understanding of the network of gene expression and regulation in higher eukaryotes has been taken to a new level. MicroRNAs may become new biological markers for disease diagnosis, even serving as drug targets or as a target mimic for new molecule drug development, which may provide a new approach of treatment for human diseases. Cyagen’s bioinformatics team has integrated information from primary microRNA databases worldwide to develop a microRNA knockout mouse database with powerful bioinformatics functions that uses AI to select and design the optimal models using all available data.
Through the artificial intelligence (AI)-driven combination of AlphaKnockout Gene Editing Expert System and CRISPR/Cas technology, Cyagen has developed the Smart-CRISPR™ Cell Gene Editing System. Smart-CRISPR™ is more efficient in gene cleavage than CRISPR/Cas technology alone and can easily accomplish multiple knockout strategies in cell lines - such as frameshift mutation, fragment knockout, and multiple gene knockout - to provide scientific solutions to problems such as protein-positive residues.